Night Shift Work, On-shift Napping, and Endothelial Function: A Pilot Study

Sponsor
University of Pittsburgh (Other)
Overall Status
Recruiting
CT.gov ID
NCT05436951
Collaborator
(none)
15
1
2
19.1
0.8

Study Details

Study Description

Brief Summary

Cardiovascular disease (CVD) and CVD risk factors such as high blood pressure (BP) are disproportionately higher among night shift workers, including those who work in public safety and healthcare. The purpose of this pilot study is to assess feasibility of collecting data germane to key indicators of cardiovascular health (i.e., ambulatory blood pressure) repeatedly during a simulated night shift protocol. The primary outcome measure will be the number of participants for which at least 70% of required ambulatory BP measures were collected. A result of at least 10 participants/subjects will be considered feasible.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Brief on-shift nap
N/A

Detailed Description

Cardiovascular disease (CVD) and CVD risk factors such as high blood pressure (BP) are disproportionately higher among night shift workers, including those who work in public safety and healthcare. Risk of CVD events such as myocardial infarction and stroke are higher among shift workers than non-shift workers. Risk of atrial fibrillation is 1.22 times greater (95%CI 1.02, 1.45) among individuals that work 3-to-8 night shifts per month versus non-shift workers. A comprehensive explanation for why shift workers, especially night shift workers, are at greater risk of CVD is not yet available. However, some research suggests that night shift workers experience repeated exposure to sleep deprivation, which impacts normal patterns in BP and endothelial function. Endothelial dysfunction and disruption of normal BP patterns are independently linked to numerous indicators of CVD, including cardiac-related mortality.

The purpose of this pilot study is to assess feasibility of collecting data germane to key indicators of cardiovascular health (i.e., ambulatory blood pressure) repeatedly during a simulated night shift protocol. Investigators propose a laboratory-based pilot study whereby participants (volunteers) complete two conditions. Condition one will include a 12-hour simulated night shift in our lab with no napping. Condition two will involve a 12-hour simulated night shift in our lab with a 45 minute nap at 0200 hours. Participants will be asked to wear monitoring devices for approximately 48 total hours with the last 12 hours of monitoring (from 1900 to 0700) to be in our lab.

Aim 1: Assess the feasibility of collecting ambulatory BP measures (ABPM) and indicators of endothelial function at multiple time points prior to, during, and after simulated night shift work.

The primary outcome measure will be the number of participants for which at least 70% of required ambulatory BP measures were collected. A result of at least 10 participants/subjects will be considered feasible.

Aim 2: Characterize the impact of simulated night shift work and on-shift napping on BP dipping and endothelial function.

Secondary endpoints include quantifying descriptive statistics (e.g., means and standard deviations) for BP dipping and endothelial function.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
15 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Randomized crossover study designRandomized crossover study design
Masking:
None (Open Label)
Masking Description:
No masking
Primary Purpose:
Other
Official Title:
Night Shift Work, On-shift Napping, and Endothelial Function: A Pilot Study
Actual Study Start Date :
Jun 28, 2022
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Jan 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: No-nap, then brief 45-minute nap

Participants will be monitored for a total of 48 hours, including a 12-hour simulated night shift. At baseline (consent), participants are randomized to a crossover study design with two study arms (no nap, brief 45-minute nap). In this sequence, participants will perform the 12-hour simulated night shift with no nap first, undergo a minimum of 1-week washout, then return complete the 48-hour protocol again with the brief 45-minute nap.

Behavioral: Brief on-shift nap
The brief nap opportunity will allow for a 45-minute nap between the hours of 0200 and 0300 during the in-lab 12-hour simulated night shift.

Experimental: The brief 45-minute nap, then no-nap

Participants will be monitored for a total of 48 hours, including a 12-hour simulated night shift. At baseline (consent), participants are randomized to a crossover study design with two study arms (no nap, brief 45-minute nap). In this sequence, participants will perform the 12-hour simulated night shift with the brief 45-minute nap, undergo a 1-week minimum washout, then return to complete the 48-hour protocol again with the no-nap

Behavioral: Brief on-shift nap
The brief nap opportunity will allow for a 45-minute nap between the hours of 0200 and 0300 during the in-lab 12-hour simulated night shift.

Outcome Measures

Primary Outcome Measures

  1. Number of Participants for which at least 70% of required Ambulatory BP readings were collected [48 continuous hours for each arm/condition]

    A result of at least 10 participants will be considered feasible

Secondary Outcome Measures

  1. Average blood pressure while awake during simulated night shift [12 continuous hours for each arm/condition]

    The mean and standard deviation of blood pressure measurements taken while participant is awake during the 12-hour simulated night shift

  2. Average blood pressure while napping during simulated night shift [45 minutes]

    The mean and standard deviation of blood pressure measurements taken while participant is napping (sleeping) during the 12-hour simulated night shift that includes the 45-minute nap condition.

  3. Average Reactive Hyperemia Index (RHI) at baseline [20-30 minutes for each arm/condition]

    The mean and standard deviation RHI score for the endothelial dysfunction measurement assessed at baseline

  4. Average Reactive Hyperemia Index (RHI) after simulated night shift [20-30 minutes for each arm/condition]

    The mean and standard deviation RHI score for the endothelial dysfunction measurement assessed after the 12-hour simulated night shift

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

All participants will be working aged adults (18 years of age or older). Investigators are interested in enrolling public safety workers and healthcare workers given how often this group works night shifts.

Criteria that participants will need to address:
  1. 18 years of age or older;

  2. Currently licensed or certified as an EMS clinician, other public safety shift worker, or other type of healthcare clinicians and actively working in Western Pennsylvania as an EMT, Paramedic, Flight Nurse/Paramedic, other EMS clinician, firefighter, or other type of healthcare clinician (e.g., nurse, physician, physician assistants, patient care technician, or other healthcare clinician);

  3. a 'no' answer to #2 above is not a criterion for exclusion.

Exclusion Criteria:
  1. Having ever been diagnosed with the following: hypertension, cardiovascular disease, myocardial infarction, stroke/TIA, chronic kidney disease, liver disease, adrenal disease, thyroid disease, rheumatologic disease, hematologic disease, cancer of any type, dementia/memory loss, organ transplantation; major sleep problem; heavy alcohol use; sleep apnea or other diagnosis that is related to problems with breathing or the airway;

  2. Current pregnancy;

  3. Insomnia is NOT a criterion for exclusion.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Pittsburgh Pittsburgh Pennsylvania United States 15261

Sponsors and Collaborators

  • University of Pittsburgh

Investigators

  • Principal Investigator: P. Daniel Patterson, University of Pittsburgh

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Daniel Patterson, PhD, NRP, Associate Professor, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT05436951
Other Study ID Numbers:
  • STUDY22040156
First Posted:
Jun 29, 2022
Last Update Posted:
Jun 30, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Daniel Patterson, PhD, NRP, Associate Professor, University of Pittsburgh

Study Results

No Results Posted as of Jun 30, 2022